Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795422 | 0.87 | HTT (0.43) | SMOLMNAHTTRAB9AKDM4E | |
| SCHEMBL6787129 | 0.84 | CA12 (0.51) | CA12CA1CA2CA9GAA | |
| SCHEMBL6645984 | 0.78 | KCNH2 (0.44) | LMNARAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6794817 | 0.77 | RAB9A (0.44) | CA12CA1CA2CA9GAA | |
| SCHEMBL6793862 | 0.76 | SMO (0.40) | CA12CA1CA2CA9GAA | |
| SCHEMBL6801791 | 0.75 | NPC1 (0.46) | GAAPOLBSMOLMNAHTT | |
| SCHEMBL6788945 | 0.74 | ENPP1 (0.43) | CA12CA1CA2CA9GAA | |
| SCHEMBL6788236 | 0.74 | SMO (0.40) | GAAPOLBSMOLMNAHTT | |
| SCHEMBL6794600 | 0.74 | L3MBTL1 (0.44) | GAAPOLBSMOLMNAHTT | |
| SCHEMBL6794735 | 0.74 | GAA (0.51) | GAAPOLBSMOLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | CA12 4000/4885CA1 4466/4885CA2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.